Close Menu

Bruker

Based on PCR technology acquired from Hain Diagnostics, the test and platform enable rapid detection of TB, as well as assessment of antibiotic resistance.

Lab director Glenn George discusses trends within clinical microbiology that could set it apart from other portions of the clinical laboratory.

Siemens Healthineers CEO Bernd Montag talked about the positive impact the firm's Attelica system is having on its revenues, while Bruker discussed plans for the BioTyper platform and assays in the pipeline.

The year saw the launch of high-profile platforms as well as efforts by a number of parties to streamline mass spec technologies for the clinic.

Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.

The method could allow clinicians to more rapidly determine the best course of antibiotic treatment for patients with sepsis and other bacterial infections.

The assay combines antibody enrichment with MALDI mass spec to measure isoforms of transferrin, a protein biomarker used to track alcohol consumption.

In the last year, both Sciex and Thermo Fisher have launched clinical platforms, but whether they will prove commercial successes remains to be seen.

Pages